New hope for battling RSV in babies: major trial tests oral treatment
NCT ID NCT07402512
Summary
This study is testing a new oral liquid medicine called deurremidevir to see if it helps infants and young children with Respiratory Syncytial Virus (RSV) get better faster. About 500 children aged 1 month to 3 years with RSV will receive either the real medicine or a placebo for 5 days. The main goal is to see how quickly it resolves key RSV symptoms like wheezing and difficulty breathing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shulan(hangzhou)Hospital
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Second University Hospital Sichuan University
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.